NZ601288A - Quinoxaline-containing compounds as hepatitis c virus inhibitors - Google Patents
Quinoxaline-containing compounds as hepatitis c virus inhibitorsInfo
- Publication number
- NZ601288A NZ601288A NZ601288A NZ60128808A NZ601288A NZ 601288 A NZ601288 A NZ 601288A NZ 601288 A NZ601288 A NZ 601288A NZ 60128808 A NZ60128808 A NZ 60128808A NZ 601288 A NZ601288 A NZ 601288A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hepatitis
- virus
- compounds
- quinoxaline
- containing compounds
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT - 601288 The disclosure relates to compounds of formula (I) and (II) pharmaceutically acceptable salts, and esters thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease, wherein the variables are as defined in the specifiation. Consequently, these compounds interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present disclosure further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98795807P | 2007-11-14 | 2007-11-14 | |
| US2545808P | 2008-02-01 | 2008-02-01 | |
| NZ58539108 | 2008-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601288A true NZ601288A (en) | 2014-03-28 |
Family
ID=50542731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601288A NZ601288A (en) | 2007-11-14 | 2008-11-14 | Quinoxaline-containing compounds as hepatitis c virus inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ601288A (en) |
-
2008
- 2008-11-14 NZ NZ601288A patent/NZ601288A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005262A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors. | |
| MX2010006209A (en) | Quinoxalinyl derivatives. | |
| WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
| WO2008021733A3 (en) | Tetrazolyl acyclic hepatitis c serine protease inhibitors | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| MX2010005261A (en) | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors. | |
| WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
| MX2010006518A (en) | Macrocyclic oximyl hepatitis c serine protease inhibitors. | |
| MX2010010276A (en) | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors. | |
| WO2008019289A3 (en) | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors | |
| NZ608720A (en) | Macrocyclic proline derived hcv serine protease inhibitors | |
| WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors | |
| MX2011012155A (en) | Macrocyclic compounds as hepatitis c virus inhibitors. | |
| MX2010006210A (en) | Fluorinated tripeptide hcv serine protease inhibitors. | |
| WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
| WO2008019303A3 (en) | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors | |
| WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
| WO2011049908A3 (en) | Bismacrokyclic compounds as hepatitis c virus inhibitors | |
| WO2009085978A8 (en) | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors | |
| MX2010008109A (en) | Difluorinated tripeptides as hcv serine protease inhibitors. | |
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| WO2004093798A3 (en) | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1325185, GAI, YONGHUA; 1325186, OR, YAT, SUN; 1325187, WANG, ZHE) Effective date: 20140121 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 NOV 2015 BY AJ PARK Effective date: 20141103 |
|
| LAPS | Patent lapsed |